primary outcome measure

(redirected from primary end point)

primary outcome measure

(1) The specific key measurement(s) or observation(s) used to measure the effect of experimental variables in a study, or for observational studies, to describe patterns of diseases or traits or associations with exposures, risk factors or treatment.
(2) The outcome measure or measures in a clinical trial which have the greatest or most desirable therapeutic effect.
References in periodicals archive ?
The primary end point of the Phase II study is the anti-inflammatory effect of the drug, as determined by ALT blood levels, and the secondary end points include percentage of liver fat, as measured by MRI-PDFF.
A clinical study is statistically powered based on the primary end point and, therefore, can only reliably evaluate that single question.
M2 PHARMA-December 20, 2017-Allergan and Gedeon Richter meet primary end point in phase three cariprazine study
M2 EQUITYBITES-December 20, 2017-Allergan and Gedeon Richter meet primary end point in phase three cariprazine study
The changes in intima-media thickness of the common carotid artery duringa 2-year observation period were examined as the primary end point.
The primary end point was a composite of cardiac death, stroke, reinfarction, ventricular arrhythmia, or paroxysmal atrial fibrillation within 1 month.
For the primary end point, both mepolizumab treatment arms showed statistically significant reductions in the frequency of clinically significant exacerbations of asthma compared to placebo (75mg IV, 47%, p
At the end of treatment, only 2 participants in each treatment group achieved the prespecified primary end point.
Overall, there was no benefit of one over the other" for the study's primary end point of the combined rate of death, ischemic stroke, or intracerebral hemorrhage, he said in an interview.
Major Finding: Compared with the placebo group, those in both the 7-mg and 14-mg teriflunomide groups experienced a statistically significant 30% reduction in the annualized relapse rate, which was the primary end point.
The primary end point in the investigator-blinded multicenter study, which included 168 patients aged 12-39 years, was quality of life as reflected in global scores on the validated Skindex-29 instrument after 2 weeks of therapy.